 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...127128129130131132133134135136137...858859» |
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study. (Pubmed Central) - Oct 3, 2023
Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research.
- | captisol-enabled melphalan / Generic mfg.
Trial completion date, Trial primary completion date: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov) - Oct 3, 2023
P1, N=46, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- || Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=508215, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
- | Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=356, Completed, Sponsor: Australian and New Zealand Intensive Care Research Centre
Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jun 2024 Recruiting --> Completed | N=603 --> 356
- | Ibrance (palbociclib) / Pfizer
Trial completion date: A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel. (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=559, Completed, Sponsor: Pfizer
Recruiting --> Completed | N=603 --> 356 Trial completion date: Oct 2021 --> Jan 2023
- | Trial completion date, Trial primary completion date, Tumor mutational burden: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) - Oct 3, 2023
P2, N=400, Active, not recruiting, Sponsor: Fondazione per la Medicina Personalizzata
Trial completion date: Oct 2021 --> Jan 2023 Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed, Trial completion date, Trial primary completion date: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa (clinicaltrials.gov) - Oct 3, 2023
P3, N=30, Active, not recruiting, Sponsor: Karen Klahr Miller, MD
Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2024
- || camizestrant (AZD9833) / AstraZeneca
Trial completion, Combination therapy, Metastases: AZD9833 China PK Study (clinicaltrials.gov) - Oct 3, 2023
P1, N=28, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2024 Recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Vertebral Compression Fracture Post Spine Stereotactic Body Radiotherapy: The Role of Vertebral Endplate. (Pubmed Central) - Oct 3, 2023
In this retrospective analysis, tumor disrupting the EP, disease recurrence and high SINS score increased the risk of VCF. Cement augmentation either prophylactically or immediately following SBRT is currently being studied in a prospective trial within our institution.
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Liquid biopsy, Metastases, Biopsy: ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) - Oct 3, 2023
P2, N=80, Recruiting, Sponsor: International Cancer Research Group, United Arab Emirates
Cement augmentation either prophylactically or immediately following SBRT is currently being studied in a prospective trial within our institution. Trial primary completion date: Jun 2023 --> Jan 2024
- || bemarituzumab (AMG 552) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov) - Oct 3, 2023
P1b, N=180, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2023 --> Jan 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Apr 2024 | Trial primary completion date: Mar 2025 --> Apr 2024
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Journal: The Theoretical Role for Radiotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Secondary Analysis of a Prospective Randomized Controlled Trial. (Pubmed Central) - Oct 3, 2023
P3
In this secondary analysis of a phase III randomized trial of chemotherapy alone for DLBCL, initial bulk was not shown to be significantly associated with outcomes. Prospective data comparing consolidative RT versus no RT are necessary to determine optimal treatment paradigms.
- | Imlygic (talimogene laherparepvec) / Amgen
Journal, Metastases: Synergistic Effect of TVEC and Radiotherapy in the Treatment of Advanced Melanoma. (Pubmed Central) - Oct 3, 2023
However, we did not find a significant difference in locoregional recurrence or OS. Given some promise with the combined approach and potential immune enhancement from RT, larger trials are needed to better understand the potential positive signal from our study.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal: Radiosensitizing Effects of CDK4/6 Inhibitors in Hormone Receptor-Positive and HER2-Negative Breast Cancer are through Downregulating DNA Repair Mechanism and NF-?B-Signaling Pathway. (Pubmed Central) - Oct 3, 2023
Given some promise with the combined approach and potential immune enhancement from RT, larger trials are needed to better understand the potential positive signal from our study. Our results demonstrated that combining CDK4/6 inhibitors enhanced the radiosensitivity in HR-positive and HER2-negative breast cancer cells, and conceivably radioenhancing mechanisms of CDK4/6 inhibitors are at least through lessening DNA-DSB repairing processes and weakening the activation of ERK signaling and NF-?B signaling by RT.
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open: TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=90, Recruiting, Sponsor: AstraZeneca
Our results demonstrated that combining CDK4/6 inhibitors enhanced the radiosensitivity in HR-positive and HER2-negative breast cancer cells, and conceivably radioenhancing mechanisms of CDK4/6 inhibitors are at least through lessening DNA-DSB repairing processes and weakening the activation of ERK signaling and NF-?B signaling by RT. Not yet recruiting --> Recruiting
- | Journal, Surgery: Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases. (Pubmed Central) - Oct 3, 2023
Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
- | Journal, Checkpoint inhibition, Metastases: Predictors of Hepatotoxicity in Patients with Metastatic Solid Tumors Treated with Immune Checkpoint Inhibition (ICI) and Liver-Directed SBRT. (Pubmed Central) - Oct 3, 2023
LM-SBRT did not significantly increase the risk for hepatotoxicity in patients receiving ICI when respecting the above dose constraints. Risk for hepatotoxicity appears to be driven by dual agent ICI and underlying liver disease.
- | Ibrance (palbociclib) / Pfizer
Journal: Targeting Non-Kinase Function of CDK6 to Overcome CDK4/6 Inhibitor Resistance. (Pubmed Central) - Oct 3, 2023
Our studies show that non-kinase function of CDK6 plays a critical role in palbociclib resistance. We also provide a novel therapeutic strategy to overcome CDK4/6 inhibitor resistance, thereby setting the stage for development of next generation drugs that eliminate both the kinase and non-kinase functions of this class of proteins.
- | Imdelltra (tarlatamab-dlle) / Amgen
New P3 trial: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer (clinicaltrials.gov) - Oct 3, 2023
P3b, N=0, Available, Sponsor: Amgen
- ||| FWD1802 / Shenzhen Forward Pharma
New P1 trial, Combination therapy, Monotherapy, Metastases: A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. (clinicaltrials.gov) - Oct 3, 2023
P1, N=99, Recruiting, Sponsor: Forward Pharmaceuticals Co., Ltd.
- | Lumakras (sotorasib) / Amgen
Journal: Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway. (Pubmed Central) - Oct 2, 2023
These datas suggested that SalF could effectively inhibit the growth of lung tumors with KRAS G12D mutation. SalF may be a novel inhibitor against KRAS G12D, providing a strong theoretical basis for the clinical treatment of lung cancer with KRAS mutations.
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical, P2 data, P3 data, Review, Journal: An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials. (Pubmed Central) - Oct 2, 2023
Although these drugs have been demonstrated to prolong overall survival (as well as progression-free survival (PFS) in breast cancer patients), changing the paradigm of all current knowledge, they also cause important adverse events (AEs). This review provides the latest summary and update on the safety profile of the three CDK4/6 inhibitors, as it appears from all major phase II and III randomized clinical trials regarding palbociclib, ribociclib, and abemaciclib, including the most relevant 15 clinical trials.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Editorial: Cancer-related hypercalcemia and potential treatments. (Pubmed Central) - Oct 2, 2023
This review provides the latest summary and update on the safety profile of the three CDK4/6 inhibitors, as it appears from all major phase II and III randomized clinical trials regarding palbociclib, ribociclib, and abemaciclib, including the most relevant 15 clinical trials. No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: The antifracture efficacy of vitamin D in adults - are we assessing it reliably? A systematic review. (Pubmed Central) - Oct 2, 2023
The analysed studies did not conclusively assess the vitamin D antifracture efficacy in patients with prestudy low serum vitamin levels, due to the lack of assessment of whether sufficient doses of vitamin D were used. They informed about the relevant doses and preparations of vitamin D in particular groups (specific fracture risk, age, place of residence) only.
- | New P2 trial: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 2, 2023
P2, N=174, Not yet recruiting, Sponsor: Northwestern University
- ||| onCARlytics (CF33-CD19) / Imugene, VAXinia (CF33-hNIS) / Imugene
New P1 trial: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS) (clinicaltrials.gov) - Oct 2, 2023
P1, N=52, Not yet recruiting, Sponsor: Imugene Limited
- | Retrospective data, Journal: Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study. (Pubmed Central) - Oct 1, 2023
This type of information on all the different types of cancer can be useful to better understand the economic burden of the disease and can be decisive for allocating public resources and funds for research, especially in those areas where information is scarce and therefore where further studies are needed. The contribution to knowledge of the cost of oncology therapy is of great value due to its realism and scope.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Trial primary completion date: BAD: Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation (clinicaltrials.gov) - Sep 30, 2023
P=N/A, N=92, Active, not recruiting, Sponsor: 251 Hellenic Air Force & VA General Hospital
The contribution to knowledge of the cost of oncology therapy is of great value due to its realism and scope. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2023 --> Sep 2024
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change, Trial withdrawal: Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy (clinicaltrials.gov) - Sep 30, 2023
P2, N=0, Withdrawn, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2023 --> Sep 2024 N=40 --> 0 | Not yet recruiting --> Withdrawn
- || Lumakras (sotorasib) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Lung KG12Ci: RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (clinicaltrials.gov) - Sep 30, 2023
P=N/A, N=458, Active, not recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
N=40 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=300 --> 458 | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Aug 2023
- || olpasiran (AMG 890) / Amgen
Enrollment closed: A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment (clinicaltrials.gov) - Sep 30, 2023
P1, N=33, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=300 --> 458 | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Aug 2023 Recruiting --> Active, not recruiting
- ||| Tavneos (avacopan) / Amgen
Enrollment open: Avacostar - (PASS) (clinicaltrials.gov) - Sep 30, 2023
P=N/A, N=500, Recruiting, Sponsor: Vifor Fresenius Medical Care Renal Pharma
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| AVZO-021 / Avenzo Therap
Enrollment open: ARTS-021-1001: Study of AVZO-021 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Sep 30, 2023
P1/2, N=192, Recruiting, Sponsor: Allorion Therapeutics Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD), Lumakras (sotorasib) / Amgen
Specialized Palliative Care in a 54 y/o pat with RAS G12C-mutated NSCLC in need of high-flow oxygen at dischargement: An ethical and logistic dilemma (Hall A) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1575;
Treatment with carboplatin pemetrexed, and pembrolizumab was initiated. EOL-communication in cancer patients on oral targeted drugs is challenged by prognostic uncertainty and difficulties with decision making on doctor
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Multiple myeloma: Antiresorptive therapy in patients with osteolytic lesions and impaired renal function (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1517;
P=N/A
MYRIAM provides essential insights into use of ART in patients with osteolytic lesions and MM, with or without impaired renal function in daily practice in Germany. ART is widely used indicating that the majority of patients is treated according to guidelines.
- Ibrance (palbociclib) / Pfizer
CDK4/6 inhibition in advanced chordoma: results from the NCT PMO-1601 Trial (Hall D) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1417;
Palbociclib monotherapy resulted in modest tumor activity with manageable toxicity. Combination therapies should be considered to improve efficacy.
- Lumakras (sotorasib) / Amgen
Biomarker subgroup analyses of the phase III study CodeBreaK 200 comparing sotorasib to docetaxel in pretreated patients with KRAS G12C-mutated non-small cell lung cancer (X5) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1383;
Clinical benefit observed with sotorasib versus docetaxel was consistent across biomarker-defined subgroups. Hypothesis-generating signals were obtained that may guide personalized predictors of drug combination strategies for KRAS G12C inhibition in NSCLC.
- Lumakras (sotorasib) / Amgen
Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Expanded Access Program in Germany (X5) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1379;
These first results from a real-world population in Germany confirm promising effectiveness of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutation seem to derive less benefit.
- Blincyto (blinatumomab) / Astellas, Amgen
Cellular immune status before therapy and outcomes in ALL-Patients receiving Blinatumomab: A single center retrospective analysis (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1101;
Differences were not statistically significant. Larger studies are needed to further investigate the influence of T-cell compartment on the response to Blinatumomab therapy.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Complete remission after sequential Inotuzumab, Blinatumomab and chemotherapy with concurrent donor lymphocyte infusions in relapsed pre-B-ALL after allogeneic stem cell transplantation. (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1098;
A cytoreductive therapy with Doxorubicin 45mg/m 2 , Vincristine 2mg and a second DLI-application (1.5x10 7 CD3+cells/kg) followed in month four...Temporary, a hepatic GvHD grade I was observed, which was treated with budesonide orally...In conclusion, our case demonstrates that co-administration of DLI, InO, Blina and chemotherapy is feasible without severe GvHD. Given these promising results, this
- The tumor microenvironment as a site for additional tumor driving activities in colorectal cancer: known data and perspectives (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1061;
The addition of an AAT to a chemotherapy will result in a prolongation of either progression free or overall survival time as was shown for bevacizumab and capecitabine in the CAIRO3 study (3), for Aflibercept in the VELOUR study (4), for Ramucirumab in the RAISE Study (5), for Regorafenib in the CORRECT study (6), and for TAS-102 in the RECOURSE study (7)...The mechanism may be transferred to other tumor entities. The contribution of modifications of the immuncheque therapy with respect to a blockade of TME cells demands further investigations.
- Blincyto (blinatumomab) / Astellas, Amgen
Future treatment of pediatric patients with precursor B ALL (Hall D) - Sep 30, 2023 - Abstract #DGHO2023DGHO_816;
The contribution of modifications of the immuncheque therapy with respect to a blockade of TME cells demands further investigations. Gezielte zellul
- Prolia (denosumab) / Amgen, Daiichi Sankyo
The influence of the dental infection focus search in the context of oncological treatment (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_743;
In most of the cases, dental treatment did not have an impact on the start or continuation of the oncological treatment. Whether prospective dental assessment prior to treatment might have an impact on survival rates remains to be elucidated.
- Routine care of patients with immune thrombocytopenia (ITP) by resident haematologists in Germany 2020-2021 (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_622;
Most patients received eltrombopag and romiplostim. Avatrombopag is being prescribed increasingly; fostamatinib is still being prescribed very cautiously.
- Ibrance (palbociclib) / Pfizer
Risk score assessment in clinical routine including gene expression testing - Interim Results of the non-interventional study PERFORM evaluating Palbociclib in Combination with Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_541;
Median age was 68 years, 92% were postmenopausal, and 39% presented with de novo ABC whereas 61% had relapse from EBC. Gene expression tests at ID, to predict benefit of adjuvant chemotherapy have been performed in just 3% (Oncotype DX in 50%, Endopredict in 44% and Mammaprint in 6%, respectively).
- Blincyto (blinatumomab) / Astellas, Amgen
The impact of Blinatumomab treatment on the T-cell pool in BCP-ALL in children and adolescents (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_295;
T-cell proliferation tends to be stronger in MR patients. This result indicates that the intensity of the prior immunosuppressive chemotherapy might influence the response to Blinatumomab by affecting both target and effector immune cell compartments.
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study (X5) - Sep 30, 2023 - Abstract #DGHO2023DGHO_76;
P3
Conclusions : Luspatercept showed statistically meaningful HI-E, durable RBC-TI, and favorable outcomes across subgroups and many MDS mutations vs ESAs. Luspatercept safety was comparable with previous MDS reports; luspatercept may represent a new standard of Tx in TD LR-MDS.
- Elunate (fruquintinib) / Takeda
FRESCO-2: A global randomized placebo-controlled phase 3 multiregional clinical trial evaluating the efficacy and safety of oral fruquintinib in patients with refractory metastatic colorectal cancer (Hall A) - Sep 30, 2023 - Abstract #DGHO2023DGHO_52;
P3
A significant and clinically meaningful improvement in OS was observed in pts with refractory mCRC receiving F compared with P. F was well tolerated, with a safety profile consistent with the established profile for F monotherapy. FRESCO-2 results are consistent with those from FRESCO and should support F as a new treatment option in refractory mCRC.
- || Enbrel (etanercept) / Pfizer, Amgen
Review, Journal: Autocrine positive feedback of tumor necrosis factor from activated microglia proposed to be of widespread relevance in chronic neurological disease. (Pubmed Central) - Sep 30, 2023
In addition, certain psychiatric states, in isolation or as sequelae of infectious diseases such as Lyme disease and long COVID, are candidates for being understood through this approach and treated accordingly. Perispinal etanercept provides the prospect of being able to treat various chronic central nervous system illnesses, whether they are of infectious or non-infectious origin, through reversing excess TNF generation by microglia.
- | Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Journal, IO biomarker, Metastases: Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics. (Pubmed Central) - Sep 30, 2023
However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.